✨ Your Portfolio is fetched and updated from zerodha.

Biogen Pharmachem Industries Ltd.

BIOGEN

Market Cap
₹65 Cr.
P/E
0.00

Biogen Pharmachem Industries Ltd.

  • Biogen Pharmachem
  • Cerebra Integ. Tech
  • Le Lavoir
FAQs on Biogen Pharmachem Industries Ltd. Shareprice

Biogen Pharmachem has given lower returns compared to its competitors.
Biogen Pharmachem has grown at ~-11.5% over the last 1yrs while peers have grown at a median rate of 32.0%

Biogen Pharmachem is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Biogen Pharmachem is 0.0, while 3 year average PE is 55.45.
Also latest EV/EBITDA of Biogen Pharmachem is 274 while 3yr average is 190.

View FAQ's On Business
Growth Table
  • Biogen Pharmachem Industries Ltd.
  • Cerebra Integ. Tech
  • Le Lavoir
Balance Sheet
  • Biogen Pharmachem Industries Ltd.
  • Cerebra Integ. Tech
  • Le Lavoir
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Biogen Pharmachem Industries Ltd.
  • Cerebra Integ. Tech
  • Le Lavoir
Cash Flow
  • Biogen Pharmachem Industries Ltd.
  • Cerebra Integ. Tech
  • Le Lavoir
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Biogen Pharmachem Industries Ltd.
  • Cerebra Integ. Tech
  • Le Lavoir
Quarterly Results
  • Biogen Pharmachem Industries Ltd.
  • Cerebra Integ. Tech
  • Le Lavoir
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Biogen Pharmachem Industries Ltd. Financials

Biogen Pharmachem balance sheet is weak and might have solvency issues

The debt of Biogen Pharmachem is decreasing.
Latest debt of Biogen Pharmachem is -₹0.32 Crs as of Sep-24.
This is less than Mar-24 when it was -₹0.03 Crs.

The profit is oscillating.
The profit of Biogen Pharmachem is -₹0.73 Crs for TTM, ₹1.93 Crs for Mar 2024 and ₹0.46 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Biogen Pharmachem latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech